Our Innovative Research Approach

The Brain Chemistry Labs uses a novel model for drug discovery that is significantly different from the traditional pharmaceutical company. Rather than investing in brick and mortar and establishing a large, bureaucratic organization, the Institute has created a virtual model by inviting world leaders in the appropriate disciplines to perform key components of our research. This collaboration is not only unique, but very efficient and effective in rapidly advancing the research unencumbered by bureaucracy. It incorporates an innovative blend of novel discovery, exceptional human capital and a singular mission to move from cause to cure.

Learn more

 
 

A Decade of Novel Drug Development

What has been accomplished over the last decade is truly remarkable with the advancement of discovery todevelopment.  The combination of innovative field research and in lab analysis enabled us to identify a dietary neurotoxin and amino acid therapy for neurodegenerative diseases. The following captures some of the milestones along our path to a cure.

Learn more

 
 

A Focus on Patients

There are no drugs that can slow disease progression for Alzheimer’s, ALS, or Parkinson’s. The number of sufferers grows as does the cost of caring for them. The Brain Chemistry Labs model is patient focused, efficient and very cost effective.

Learn more

 
 

Cost Efficient Research

It typically takes a pharmaceutical company 15 years and often $1 billion to bring a drug through the necessary clinical trials for FDA approval. Over the last decade we have spent $15 million and currently have a new drug, L-serine, in human clinical trials for both Alzheimer’s and ALS.

About 90% of our revenues go towards medical research, 7% to management and administration and 3% to fundraising. Over the past 10 years over 40% of our funds have been furnished by our Board of Directors. Going forward we will need between $1.5 and $2 million annually for our operations and ongoing research and additional funds for new clinical trials.

We need and would deeply appreciate your financial support.

Learn more

 

The Latest News from Brain Chemistry Labs


Environmental Toxin May Increase Risk of Alzheimer's

Proceedings of the Royal Society: For the first time, scientists have observed brain tangles in an animal model through exposure to environmental toxin.


L-Serine's Potential for ALS Patients 

Ogimi Village is Renowned for its Aging Population. We sought to determine if the L-serine content of their diet could account for their neurological health.


L-Serine Safe for ALS Patients

We completed a Phase I ALS trial —to demonstrate the safety of the naturally occurring amino acid, L-serine, in humans—that showed encouraging signs of slowing disease progression among enrolled patients.


FDA Approves Phases II and IIa Clinical Trial of L-Serine

See links to FDA-approved Phase II clinical trial of L-serine for ALS patients and Phase IIa clinical trial of L-serine for early stage Alzheimer's patients 

 

Brain Chemistry Labs' Movie Selected for Newport Beach Film Festival

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Integer sollicitudin velit eget consequat consectetur. Vivamus condimentum elit nec magna aliquet cursus. Aliquam pellentesque tortor sem, eget viverra magna rhoncus et. Phasellus et orci mollis, imperdiet eros quis, pretium massa. Nunc placerat lobortis mi eget aliquam.


Dr. Paul Alan Cox Gives TED Talk at Jackson Hole

Paul Alan Cox is a Harvard Ph.D. who has searched for new medicines from plants used by traditional healers in the Pacific and Southeast Asia. For these efforts TIME magazine named him one of 11 "Heroes of Medicine." His efforts in preserving island rain forests were recognized with the Goldman Environmental Prize.